Hedgepath Pharmaceuticals, Inc.

Calculating rank

USPTO Granted Patents = 5

Forward Citations = 1

Loading Chart...

2 inventors (with patents filed for the assignee):

Nicholas J Virca (5 out of 5 patents)

Francis E O'Donnell, Jr (5 out of 10 patents)

5 patents: Sort by Forward Citations

1. 10363252 - Treatment of prostate cancer using hedgehog pathway inhibitors (2019-07-30),

2. 10328072 - Treatment of lung cancer using hedgehog pathway inhibitors (2019-06-25),

3. 9968600 - Treatment and prognostic monitoring of non-cancerous proliferation disorders using hedgehog pathway inhibitors (2018-05-15),

4. 9962381 - Treatment and prognostic monitoring of cancerous proliferation disorders using Hedgehog pathway inhibitors (2018-05-08),

5. 9192609 - Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors (2015-11-24),

Company Overview

Hedgepath Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for rare diseases. With a strong commitment to improving the lives of patients, Hedgepath Pharmaceuticals is dedicated to advancing novel treatments that address unmet medical needs. The company's pipeline includes promising candidates for various rare diseases, with a focus on neurology and oncology. Through strategic partnerships and collaborations, Hedgepath Pharmaceuticals aims to bring transformative therapies to patients in need.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

5 Patents

#95 in Tampa, FL

#1,716 in Florida

#51,669 in US

Tampa, FL, United States of America